SLAIN2

Summary

SLAIN2 (SLAIN family member 2, HGNC:29282) is a protein-coding gene on chromosome 4p11, encoding SLAIN motif-containing protein 2 (Q9P270). Binds to the plus end of microtubules and regulates microtubule dynamics and microtubule organization.

Involved in cytoplasmic microtubule organization; microtubule nucleation; and positive regulation of microtubule polymerization. Located in centrosome; cytosol; and microtubule plus-end.

Source: NCBI Gene 57606 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 116 total
• MANE Select transcript: NM_020846

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29282
Approved symbol	SLAIN2
Name	SLAIN family member 2
Location	4p11
Locus type	gene with protein product
Status	Approved
Aliases	FLJ21611
Ensembl gene	ENSG00000109171
Ensembl biotype	protein_coding
OMIM	610492
Entrez	57606

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 7 protein_coding, 1 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000264313, ENST00000505131, ENST00000506375, ENST00000510595, ENST00000512093, ENST00000888698, ENST00000917426, ENST00000942829, ENST00000942830

RefSeq mRNA: 1 — MANE Select: NM_020846 NM_020846

CCDS: CCDS47051

Canonical transcript exons

ENST00000264313 — 8 exons

Exon	Start	End
ENSE00000714284	48382568	48382927
ENSE00000714290	48420125	48420443
ENSE00001504518	48379690	48379848
ENSE00002072714	48422011	48426201
ENSE00002073420	48377896	48378060
ENSE00003562075	48383647	48383784
ENSE00004283636	48341529	48342128
ENSE00004283637	48369849	48369997

Expression profiles

Bgee: expression breadth ubiquitous, 262 present calls, max score 97.99.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 14.1718 / max 163.6229, expressed in 1803 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
47567	9.7059	1787
47566	3.3735	1526
47565	0.5462	283
47564	0.3411	139
47570	0.2051	70

Top tissues by expression

262 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
tibialis anterior	UBERON:0001385	97.99	gold quality
left ventricle myocardium	UBERON:0006566	97.51	gold quality
deltoid	UBERON:0001476	97.25	gold quality
sperm	CL:0000019	97.18	gold quality
calcaneal tendon	UBERON:0003701	97.05	gold quality
epithelial cell of pancreas	CL:0000083	96.95	gold quality
cardiac muscle of right atrium	UBERON:0003379	96.62	gold quality
hindlimb stylopod muscle	UBERON:0004252	96.60	gold quality
oviduct epithelium	UBERON:0004804	96.00	gold quality
muscle of leg	UBERON:0001383	95.98	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	95.92	gold quality
skeletal muscle tissue	UBERON:0001134	95.90	gold quality
vastus lateralis	UBERON:0001379	95.90	gold quality
skeletal muscle organ	UBERON:0014892	95.88	gold quality
gastrocnemius	UBERON:0001388	95.82	gold quality
biceps brachii	UBERON:0001507	95.70	gold quality
colonic epithelium	UBERON:0000397	95.65	gold quality
cortical plate	UBERON:0005343	95.58	gold quality
muscle tissue	UBERON:0002385	95.50	gold quality
smooth muscle tissue	UBERON:0001135	95.41	gold quality
quadriceps femoris	UBERON:0001377	95.16	gold quality
tendon	UBERON:0000043	95.14	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	95.11	gold quality
ileal mucosa	UBERON:0000331	94.73	gold quality
popliteal artery	UBERON:0002250	94.70	gold quality
tibial artery	UBERON:0007610	94.69	gold quality
cauda epididymis	UBERON:0004360	94.67	gold quality
upper arm skin	UBERON:0004263	94.45	gold quality
myocardium	UBERON:0002349	94.37	gold quality
stromal cell of endometrium	CL:0002255	94.24	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	8.07

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

344 targeting SLAIN2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4262	100.00	73.26	3931
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-3134	100.00	66.43	777
HSA-MIR-6856-5P	100.00	65.47	1298
HSA-MIR-6758-5P	100.00	66.21	1470
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-12118	100.00	65.88	1270
HSA-MIR-518D-5P	100.00	67.51	979
HSA-MIR-518E-5P	100.00	67.66	954
HSA-MIR-518F-5P	100.00	67.51	979
HSA-MIR-519A-5P	100.00	67.66	954
HSA-MIR-519B-5P	100.00	67.66	954
HSA-MIR-519C-5P	100.00	67.66	954
HSA-MIR-520C-5P	100.00	67.51	979
HSA-MIR-522-5P	100.00	67.66	954
HSA-MIR-523-5P	100.00	67.66	954

Literature-anchored findings (GeneRIF, showing 2)

• Results identify SLAIN2 as a key component of microtubule plus end interaction networks. (PMID:21646404)
• catastrophe inhibition by SLAIN2 and CLASP1 supports mesenchymal cell shape in soft 3D matrices by enabling microtubules to perform a load-bearing function. (PMID:27939686)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	slain2	ENSDARG00000032114
mus_musculus	Slain2	ENSMUSG00000036087
rattus_norvegicus	Slain2	ENSRNOG00000002271

Paralogs (1): SLAIN1 (ENSG00000139737)

Protein

Protein identifiers

SLAIN motif-containing protein 2 — Q9P270 (reviewed: Q9P270)

All UniProt accessions (5): Q9P270, A0A024R9T6, D6REM5, D6RIF6, H0Y9L2

UniProt curated annotations — full annotation on UniProt →

Function. Binds to the plus end of microtubules and regulates microtubule dynamics and microtubule organization. Promotes cytoplasmic microtubule nucleation and elongation. Required for normal structure of the microtubule cytoskeleton during interphase.

Subunit / interactions. Interacts with CLIP1, CLIP2, CKAP5, CLASP1, MAPRE1 and MAPRE3.

Subcellular location. Cytoplasm. Cytoskeleton.

Tissue specificity. Widely expressed with highest levels in adult liver, testis and ovary, and lowest levels in adult pancreas and spleen and in fetal brain.

Post-translational modifications. Is highly phosphorylated during mitosis, but not during interphase. The highly phosphorylated form does not localize at microtubule plus ends and does not interact with MAPRE1 or CKAP5.

Domain organisation. The N-terminus forms a two-stranded coiled coil.

Similarity. Belongs to the SLAIN motif-containing family.

RefSeq proteins (1): NP_065897* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR026179	Slain	Family

Pfam: PF15301

UniProt features (44 total): modified residue 24, compositionally biased region 9, region of interest 4, sequence conflict 2, chain 1, site 1, mutagenesis site 1, helix 1, coiled-coil region 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
3RDV	X-RAY DIFFRACTION	1.75

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9P270-F1	54.69	0.11

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 581 (important for interaction with clip1)

Post-translational modifications (24): 1, 43, 48, 63, 88, 134, 147, 160, 179, 247, 250, 251, 254, 315, 323, 377, 391, 413, 433, 456 …

Mutagenesis-validated functional residues (1):

Position	Phenotype
581	abolishes interaction with clip1.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 239 (showing top): GOBP_REGULATION_OF_PROTEIN_POLYMERIZATION, GOBP_CYTOPLASMIC_MICROTUBULE_ORGANIZATION, GOBP_REGULATION_OF_MICROTUBULE_BASED_PROCESS, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GOBP_MICROTUBULE_NUCLEATION, GOBP_POSITIVE_REGULATION_OF_ORGANELLE_ORGANIZATION, GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS, GOCC_MICROTUBULE_ORGANIZING_CENTER, GOBP_POSITIVE_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS, GOBP_POSITIVE_REGULATION_OF_MICROTUBULE_POLYMERIZATION_OR_DEPOLYMERIZATION, GOBP_REGULATION_OF_MICROTUBULE_POLYMERIZATION, GOCC_CENTROSOME, GOBP_REGULATION_OF_PROTEIN_CONTAINING_COMPLEX_ASSEMBLY, chr4p11, GOBP_POSITIVE_REGULATION_OF_PROTEIN_CONTAINING_COMPLEX_ASSEMBLY

GO Biological Process (4): microtubule nucleation (GO:0007020), positive regulation of microtubule polymerization (GO:0031116), cytoplasmic microtubule organization (GO:0031122), regulation of microtubule polymerization (GO:0031113)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (6): centrosome (GO:0005813), cytosol (GO:0005829), microtubule cytoskeleton (GO:0015630), cytoplasm (GO:0005737), cytoskeleton (GO:0005856), microtubule plus-end (GO:0035371)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
microtubule polymerization	3
microtubule cytoskeleton organization	2
cellular anatomical structure	2
positive regulation of microtubule polymerization or depolymerization	1
regulation of microtubule polymerization	1
positive regulation of protein polymerization	1
positive regulation of supramolecular fiber organization	1
supramolecular fiber organization	1
regulation of microtubule polymerization or depolymerization	1
regulation of protein polymerization	1
regulation of supramolecular fiber organization	1
binding	1
centriole	1
microtubule organizing center	1
cytoplasm	1
cytoskeleton	1
intracellular anatomical structure	1
intracellular membraneless organelle	1
microtubule end	1

Protein interactions and networks

STRING

1706 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SLAIN2	CKAP5	Q14008	608
SLAIN2	CLASP1	Q7Z460	554
SLAIN2	SLC10A4	Q96EP9	539
SLAIN2	CLASP2	O75122	529
SLAIN2	ZC3H18	Q86VM9	528
SLAIN2	OCIAD1	Q9NX40	527
SLAIN2	CLASRP	Q8N2M8	501
SLAIN2	NFXL1	Q6ZNB6	496
SLAIN2	METTL26	Q96S19	478
SLAIN2	ARHGEF10L	Q9HCE6	474
SLAIN2	FRYL	O94915	454
SLAIN2	CLIP2	Q9UDT6	445
SLAIN2	MAPRE3	Q9UPY8	443
SLAIN2	AKAP1	Q92667	426
SLAIN2	AFMID	Q63HM1	423

IntAct

68 interactions, top by confidence:

A	B	Type	Score
CKAP5	TACC1	psi-mi:“MI:0914”(association)	0.800
YWHAG	BLTP3B	psi-mi:“MI:0914”(association)	0.640
SLAIN2	YWHAH	psi-mi:“MI:0914”(association)	0.640
SLAIN2	CKAP5	psi-mi:“MI:0915”(physical association)	0.620
YWHAH	PLEKHG3	psi-mi:“MI:0914”(association)	0.610
YWHAH	BLTP3B	psi-mi:“MI:0914”(association)	0.570
YWHAQ	IGLC7	psi-mi:“MI:0914”(association)	0.530
GRB2	SH3PXD2B	psi-mi:“MI:0914”(association)	0.530
TSKS	RGPD8	psi-mi:“MI:0914”(association)	0.530
TACC3	HSPA8	psi-mi:“MI:0914”(association)	0.530
PTPRD	SLAIN2	psi-mi:“MI:0407”(direct interaction)	0.440
SLAIN2	DAPK1	psi-mi:“MI:0407”(direct interaction)	0.440
	SLAIN2	psi-mi:“MI:0407”(direct interaction)	0.440
Ogn	SLAIN2	psi-mi:“MI:0407”(direct interaction)	0.440
SLAIN2	SRPK2	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
SLAIN2	SRPK1	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
YWHAZ	SLAIN2	psi-mi:“MI:0915”(physical association)	0.400
TACC3	DHRS2	psi-mi:“MI:0914”(association)	0.350
Ckap5	CCHCR1	psi-mi:“MI:0914”(association)	0.350
CKAP5	TACC3	psi-mi:“MI:0914”(association)	0.350
MAGEA10	XPO1	psi-mi:“MI:0914”(association)	0.350
SLAIN2	TACC2	psi-mi:“MI:0914”(association)	0.350
SLAIN2	TARS3	psi-mi:“MI:0914”(association)	0.350
Xpo1	IFT56	psi-mi:“MI:0914”(association)	0.350
E7	COPE	psi-mi:“MI:0914”(association)	0.350
	SNAP23	psi-mi:“MI:0914”(association)	0.350
TUBA1A	CAPZB	psi-mi:“MI:0914”(association)	0.350
TUBA1A	KIF2A	psi-mi:“MI:0914”(association)	0.350
ESR1	ESYT2	psi-mi:“MI:0914”(association)	0.350

BioGRID (161): SLAIN2 (Affinity Capture-MS), SLAIN2 (Proximity Label-MS), SLAIN2 (Proximity Label-MS), SLAIN2 (Proximity Label-MS), SLAIN2 (Proximity Label-MS), SLAIN2 (Proximity Label-MS), SLAIN2 (Affinity Capture-MS), SLAIN2 (Affinity Capture-MS), ADRBK1 (Affinity Capture-MS), JARID2 (Affinity Capture-MS), P4HA1 (Affinity Capture-MS), PCM1 (Affinity Capture-MS), TRIM27 (Affinity Capture-MS), FXR1 (Affinity Capture-MS), YBX3 (Affinity Capture-MS)

ESM2 similar proteins: A0A088MLT8, A0JNC2, A2AQ25, A6H7A8, B3KU38, B5DF41, E1BEQ5, E9PSK7, O15079, O60271, Q157S1, Q3MHV6, Q4VCS5, Q58A65, Q5F3B1, Q5R595, Q5T5P2, Q62739, Q68ED7, Q68FF7, Q7KW14, Q7PQ25, Q80TM6, Q80U23, Q86YP4, Q8CHY6, Q8CI08, Q8IY63, Q8ND83, Q8TEK3, Q8VHG2, Q8VHI6, Q8VHR5, Q8WXI9, Q920B0, Q921D9, Q96QF0, Q99LB0, Q9C0H9, Q9DCB4

Diamond homologs: A8E4V2, Q0VA20, Q3MHV6, Q5XG16, Q68FF7, Q7SXC6, Q8CI08, Q8ND83, Q9P270

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
SMURF1	unknown	SLAIN2	ubiquitination

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 83 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Activation of BAD and translocation to mitochondria	5	76.1×	3e-07
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex	5	67.2×	4e-07
SARS-CoV-1 targets host intracellular signalling and regulatory pathways	5	67.2×	4e-07
Activation of BH3-only proteins	5	49.6×	2e-06
RHO GTPases activate PKNs	5	31.7×	2e-05
Intrinsic Pathway for Apoptosis	5	29.3×	2e-05
Translocation of SLC2A4 (GLUT4) to the plasma membrane	8	24.7×	1e-07
Apoptosis	6	20.1×	2e-05

GO biological processes:

GO term	Partners	Fold	FDR
mitotic spindle organization	7	27.6×	3e-06
cerebral cortex development	5	14.9×	3e-03
microtubule cytoskeleton organization	7	12.3×	4e-04
intracellular protein localization	6	9.1×	4e-03
cell division	9	6.0×	3e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

116 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	98
Likely benign	2
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

1747 predictions. Top by Δscore:

Variant	Effect	Δscore
4:48341830:C:G	donor_gain	1.0000
4:48342125:GCTG:G	donor_gain	1.0000
4:48369845:CTAG:C	acceptor_loss	1.0000
4:48369846:TAGGC:T	acceptor_loss	1.0000
4:48369847:A:AT	acceptor_loss	1.0000
4:48369848:GGCT:G	acceptor_gain	1.0000
4:48377894:A:AG	acceptor_gain	1.0000
4:48377895:G:GG	acceptor_gain	1.0000
4:48379687:A:AG	acceptor_gain	1.0000
4:48379687:AAG:A	acceptor_gain	1.0000
4:48379688:A:G	acceptor_gain	1.0000
4:48379688:AGGTA:A	acceptor_loss	1.0000
4:48379689:G:GC	acceptor_loss	1.0000
4:48379689:GGT:G	acceptor_gain	1.0000
4:48379689:GGTA:G	acceptor_gain	1.0000
4:48379844:AGAAA:A	donor_gain	1.0000
4:48379845:GAAA:G	donor_gain	1.0000
4:48379845:GAAAG:G	donor_gain	1.0000
4:48379846:AAA:A	donor_gain	1.0000
4:48379846:AAAG:A	donor_loss	1.0000
4:48379847:AA:A	donor_gain	1.0000
4:48379848:AGTA:A	donor_loss	1.0000
4:48379849:G:GG	donor_gain	1.0000
4:48379850:TAA:T	donor_loss	1.0000
4:48383639:T:A	acceptor_gain	1.0000
4:48383642:TGCA:T	acceptor_loss	1.0000
4:48383643:GCAG:G	acceptor_loss	1.0000
4:48383644:CA:C	acceptor_loss	1.0000
4:48383645:A:AG	acceptor_gain	1.0000
4:48383645:A:C	acceptor_loss	1.0000

AlphaMissense

3745 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
4:48341789:T:A	L17Q	1.000
4:48341789:T:C	L17P	1.000
4:48341792:A:C	Q18P	1.000
4:48341798:T:C	L20P	1.000
4:48341800:G:A	V21M	1.000
4:48341810:T:A	L24Q	1.000
4:48341810:T:C	L24P	1.000
4:48341819:A:C	Q27P	1.000
4:48341821:A:G	N28D	1.000
4:48341831:T:C	L31P	1.000
4:48379828:T:C	L281P	1.000
4:48379830:G:C	A282P	1.000
4:48379831:C:A	A282D	1.000
4:48379834:G:C	R283P	1.000
4:48379840:A:C	Q285P	1.000
4:48382571:T:C	L289P	1.000
4:48341776:G:A	E13K	0.999
4:48341779:G:A	V14M	0.999
4:48341780:T:C	V14A	0.999
4:48341783:G:C	R15P	0.999
4:48341789:T:G	L17R	0.999
4:48341793:G:C	Q18H	0.999
4:48341793:G:T	Q18H	0.999
4:48341798:T:A	L20Q	0.999
4:48341810:T:G	L24R	0.999
4:48341814:G:C	E25D	0.999
4:48341814:G:T	E25D	0.999
4:48341823:C:A	N28K	0.999
4:48341823:C:G	N28K	0.999
4:48369910:T:A	W151R	0.999

dbSNP variants (sampled 300 via entrez): RS1000027730 (4:48380483 A>G), RS10000288 (4:48355510 A>G,T), RS1000090387 (4:48347898 G>A), RS10001054 (4:48406804 A>G,T), RS1000185279 (4:48384355 G>A), RS10003230 (4:48358608 G>A), RS1000335114 (4:48353751 G>A,T), RS10003458 (4:48358814 G>A,T), RS1000399923 (4:48421175 C>T), RS1000414833 (4:48413305 A>G), RS1000433119 (4:48342081 C>A,G), RS10004425 (4:48366942 T>A,C), RS1000457192 (4:48371416 T>A), RS1000458391 (4:48390617 A>G), RS1000521117 (4:48385778 G>A)

Disease associations

OMIM: gene MIM:610492 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST006462_16	Uterine fibroids	4.000000e-12
GCST007096_77	Pulse pressure	4.000000e-08
GCST007099_224	Systolic blood pressure	9.000000e-07
GCST008103_79	Bipolar disorder	1.000000e-06

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0005763	pulse pressure measurement
EFO:0006335	systolic blood pressure

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

31 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
methylmercuric chloride	affects cotreatment, decreases expression, increases expression	4
Valproic Acid	affects cotreatment, decreases expression, increases expression	4
trichostatin A	affects cotreatment, affects expression, decreases expression	3
Tretinoin	affects cotreatment, decreases expression, increases expression	3
sodium arsenite	affects cotreatment, decreases expression, increases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
FR900359	affects phosphorylation	1
geldanamycin	increases expression	1
triphenyl phosphate	affects expression	1
butyraldehyde	decreases expression	1
benzo(e)pyrene	decreases methylation	1
coumarin	increases phosphorylation	1
pentanal	decreases expression	1
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine	decreases expression	1
perfluorooctane sulfonic acid	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression, decreases expression, affects expression	1
torcetrapib	increases expression	1
abrine	increases expression	1
dorsomorphin	affects cotreatment, increases expression, decreases expression, affects expression	1
Vorinostat	decreases expression	1
Cadmium	decreases expression, increases abundance	1
Caffeine	affects phosphorylation	1
Ivermectin	decreases expression	1
Lead	decreases expression	1
Methapyrilene	decreases methylation	1
Methotrexate	increases expression	1
Dihydrotestosterone	increases expression	1
Thiram	increases expression	1
Urethane	increases expression	1
Antirheumatic Agents	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.